Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up spending, Mercer's latest survey reveals.

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Eli Lilly and Novo Nordisk NVO presently dominate this space. Mounjaro and Zepbound directly compete with Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Zepbound users face new hurdles as CVS drops the drug Eli Lilly's Zepbound faces insurance hurdles as coverage changes could spike out-of-pocket costs for millions relying on weight loss medications.